Politician(s) lobbied:Simon Harris (An Taoiseach), Department of the Taoiseach
Intent: To brief the Taoiseach on the pharmaceutical industry’s views and recommendations relating to matters of the Council of the European Union’s meetings on Employment, social policy, health and consumer affairs (EPSCO) and Competitiveness (COMPET).
Methods:Letter
Details by Method
Letter
Letter to incoming Taoiseach, congratulating him on his appointment, seeking his support regarding EPSCO and COMPET Council meetings, and extending an invitation to visit Ipsen facilities.
Politician(s) lobbied:Leo Varadkar (Minister), Department of Enterprise, Trade and Employment; Frances Fitzgerald (MEP), European Parliament
Intent: A meeting with Minister and MEP
Methods:MeetingLetter
Details by Method
Meeting
A meeting between the Tanaiste, Leo Varadkar, the IDA and Senior Executives of Ipsen and Frances Fitzgerald, Member of the European Parliament. Ipsen took the opportunity to discuss the EU pharmaceutical strategy and shared the latest data on Ireland’s performance when it comes to access to innovative medicines.
Letter
Letter was sent to Leo Varadkar to follow-up on the meeting and to outline to main points of the conversation.
Politician(s) lobbied:Leo Varadkar (Minister), Department of Enterprise, Trade and Employment
Intent: A meeting with Ministers, not achieved due to diaries
Methods:MeetingLetter
Details by Method
Meeting
A meeting between the Tanaiste, Leo Varadkar, the IDA and Senior Executives of Ipsen took place in Paris on date 16 Feb 2022. The meeting was requested as part of a Trade Mission. Ipsen took the opportunity to discuss the EU pharmaceutical strategy and shared the latest data on Ireland’s performance when it comes to access to innovative medicines.
Politician(s) lobbied:Barry Andrews (MEP), European Parliament; Frances Fitzgerald (MEP), European Parliament
Intent: To brief the MEPs on the Pharmaceutical Industry’s views and recommendations for the EU pharmaceutical Strategy and urge Ireland to position itself in this European policy development as an innovator country, to ensure that any opening of intellectual rights for medicines takes great care to achieve the objective of stimulating new solutions for unmet medical needs and to protect existing innovation. To discuss the European Action Plan on Rare Diseases.